A Phase 2 interventional study of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with IFN-α in Hepatitis B, Chronic, sponsored by Brii Biosciences Limited. Completed at 28 sites in 6 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Brii Biosciences Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.
Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 173rd largest by enrollment of the 273 interventional ones that give a count, is one of 25 that started in 2021, is one of 72 in phase 2, and was the 212th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:
Jiyan Liu · Sites in China
Ages 18–65
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Fujian Akeylink Biotechnology Co., Ltd. · Sites in China
Ages 35–65
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Zhiliang Gao · Sites in China
Ages 18–65 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
375 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 85 · Phase 3 27 · Phase 4 73
First in 2000; this study’s year is marked. 25 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is close to the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 120 across the 273 interventional studies, 500 across the 99 observational. Of the 151 that completed or were terminated, 29 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
167 of 375 have an industry lead sponsor. The 10 most frequent:
Brii Biosciences Limited is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Brii Biosciences Limited has 5 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
39 of the studies in Hepatitis B, Chronic with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07090759Phase 3Fujian Akeylink Biotechnology Co., Ltd.To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment | 2026-12-01 |
| NCT07246889Phase 3Ausper Biopharma Co., Ltd.Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) | 2026-12-18 |
| NCT07307586Phase 3Zhigang RenA Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B | 2026-12-31 |
| NCT07203118Phase 3Xi'an Xintong Pharmaceutical Research Co.,Ltd.A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B | 2027-06-30 |
| NCT02863757Humanity and Health Research CentreFollow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease | 2026-12 |
Add all 39 to your calendar (.ics) → With an account.
Among the 375 studies in Hepatitis B, Chronic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive BRII-835 (VIR-2218) for 32 weeks
Drug: BRII-835 (VIR-2218)
Participants will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with IFN-α up to Week 40
Drug: BRII-835 (VIR-2218) · Biological: BRII-179 (VBI-2601) with IFN-α
Participant will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) up to Week 40
Drug: BRII-835 (VIR-2218) · Biological: BRII-179 (VBI-2601)
BRII-835 (VIR-2218) will be given by subcutaneous injection
BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
BRII-179 (VBI-2601) will be administered by intramuscular injection
Percentage of Participants With Sustained HBsAg Loss During the 48-week Follow-up Period After NRTI Withdrawal
Sustained HBsAg loss was defined as undetectable HBsAg \< 0.05 IU/mL for at least 24 weeks during the 48-week follow-up period after NRTI withdrawal
Time frame: Up to Week 96
Number of Participants With Adverse Events (AE)
Treatment-emergent adverse events (TEAEs) were summarized for each cohort
Time frame: Up to Week 96
Number of Participants With Serious Adverse Events (SAE)
Serious adverse events (SAEs) were summarized for each cohort
Time frame: Up to Week 96
Number of Participants With Abnormalities in Clinical Laboratory Tests
Treatment-emergent laboratory abnormalities of at least grade 3 are summarized for each cohort
Time frame: Up to Week 96
Percentage of Participants Meeting the NRTI Withdrawal Criteria at Week 44
Percentage of participants meeting the NRTI withdrawal criteria at Week 44 was summarized for each cohort
Time frame: Week 44
Percentage of Participants With HBsAg Loss With or Without Antibodies to Hepatitis B Surface Antigen (Anti-HBs) at Week 72
Percentage of participants with HBsAg loss with or without antibodies to hepatitis B surface antigen (anti-HBs) at Week 72 was summarized for each cohort
Time frame: Week 72
Percentage of Participants With HBsAg Loss at Any Timepoint
Percentage of participants with HBsAg loss at any timepoint was summarized for each cohort
Time frame: Up to Week 72
Percentage of Participants With HBsAg Seroconversion at Any Timepoint
Percentage of participants with HBsAg seroconversion at any timepoint was summarized for each cohort
Time frame: Up to Week 72
Change From Baseline in Serum HBsAg at Week 72
Change from baseline in serum HBsAg at Week 72 was summarized for each cohort
Time frame: Week 72
Percentage of Participants With HBeAg Loss and/or Anti-HBe Seroconversion at Week 44 in Those Who Were HBeAg Positive at Screening
Percentage of participants with HBeAg loss and/or anti-HBe seroconversion at Week 44 in those who were HBeAg positive at screening was summarized for each cohort
Time frame: Week 44
Change From Baseline in Serum Appearance and/or Titer of Anti-HBs at Any Timepoint
Change from baseline in serum appearance and/or titer of anti-HBs at any timepoint was summarized for each cohort
Time frame: Up to Week 72
| Milestone | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Started | 11 | 39 | 41 |
| Completed | 10 | 37 | 40 |
| Not completed | 1 | 2 | 1 |
Sustained HBsAg loss was defined as undetectable HBsAg \< 0.05 IU/mL for at least 24 weeks during the 48-week follow-up period after NRTI withdrawal
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Percentage of Participants With Sustained HBsAg Loss During the 48-week Follow-up Period After NRTI Withdrawal | 0 | 0 | 0 |
Treatment-emergent adverse events (TEAEs) were summarized for each cohort
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Number of Participants With Adverse Events (AE) | 10 | 37 | 37 |
Serious adverse events (SAEs) were summarized for each cohort
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAE) | 0 | 3 | 6 |
Treatment-emergent laboratory abnormalities of at least grade 3 are summarized for each cohort
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| >= grade 3 hematology abnormalities | 1 | 1 | 1 |
| >= grade 3 lymphocytes decreased | 1 | 1 | 1 |
| >= grade 3 coagulation abnormalities | 0 | 0 | 0 |
| >= grade 3 chemistry abnormalities | 0 | 2 | 2 |
| >= grade 3 creatine kinase increased | 0 | 2 | 2 |
Percentage of participants meeting the NRTI withdrawal criteria at Week 44 was summarized for each cohort
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Percentage of Participants Meeting the NRTI Withdrawal Criteria at Week 44 | 0 | 0 | 1 |
Percentage of participants with HBsAg loss with or without antibodies to hepatitis B surface antigen (anti-HBs) at Week 72 was summarized for each cohort
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Percentage of Participants With HBsAg Loss With or Without Antibodies to Hepatitis B Surface Antigen (Anti-HBs) at Week 72 | 0 | 0 | 0 |
Percentage of participants with HBsAg loss at any timepoint was summarized for each cohort
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Percentage of Participants With HBsAg Loss at Any Timepoint | 0 | 0 | 1 |
Percentage of participants with HBsAg seroconversion at any timepoint was summarized for each cohort
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Percentage of Participants With HBsAg Seroconversion at Any Timepoint | 0 | 0 | 1 |
Change from baseline in serum HBsAg at Week 72 was summarized for each cohort
| log10 IU/mL | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Change From Baseline in Serum HBsAg at Week 72 | -1.150 ± 0.596 | -0.913 ± 0.461 | -1.018 ± 0.440 |
Percentage of participants with HBeAg loss and/or anti-HBe seroconversion at Week 44 in those who were HBeAg positive at screening was summarized for each cohort
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| HBeAg loss | 1 | 3 | 3 |
| HBeAg seroconversion | 0 | 0 | 0 |
Change from baseline in serum appearance and/or titer of anti-HBs at any timepoint was summarized for each cohort
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| No anti-HBs response | 9 | 10 | 9 |
| Anti-HBs response detected with anti-HBs <= 10 IU/L | 1 | 5 | 6 |
| Anti-HBs response detected with anti-HBs > 10 IU/L | 0 | 22 | 25 |
| Not evaluable | 0 | 2 | 1 |
Collected over Up to 96 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Cohort B | 0/39 (0%) | 3/39 (7.7%) | 37/39 (94.9%) |
| Cohort C | 0/41 (0%) | 6/41 (14.6%) | 37/41 (90.2%) |
| Event | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/10 | 1/39 | 1/41 |
| AppendicitisInfections and infestations | 0/10 | 1/39 | 0/41 |
| Oesophageal cystCongenital, familial and genetic disorders | 0/10 | 1/39 | 0/41 |
| Subarachnoid hemorrhageNervous system disorders | 0/10 | 1/39 | 0/41 |
| Duodenal ulcerGastrointestinal disorders | 0/10 | 0/39 | 1/41 |
| Small intestinal obstructionGastrointestinal disorders | 0/10 | 0/39 | 1/41 |
| Ludwig anginaInfections and infestations | 0/10 | 0/39 | 1/41 |
| Acute myocardial infarctionCardiac disorders | 0/10 | 0/39 | 1/41 |
| Coronary artery diseaseCardiac disorders | 0/10 | 0/39 | 1/41 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/10 | 0/39 | 1/41 |
| Event | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 3/10 | 27/39 | 7/41 |
| Injection site reactionGeneral disorders | 6/10 | 22/39 | 20/41 |
| HeadacheNervous system disorders | 1/10 | 23/39 | 10/41 |
| FatigueGeneral disorders | 2/10 | 22/39 | 11/41 |
| COVID-19Infections and infestations | 4/10 | 15/39 | 19/41 |
| PyrexiaGeneral disorders | 0/10 | 16/39 | 3/41 |
| Back painMusculoskeletal and connective tissue disorders | 3/10 | 0/39 | 1/41 |
| NauseaGastrointestinal disorders | 2/10 | 8/39 | 1/41 |
| DiarrheaGastrointestinal disorders | 1/10 | 7/39 | 4/41 |
| DizzinessNervous system disorders | 0/10 | 6/39 | 1/41 |
All randomized set included all randomized participants, irrespective of whether they received any study treatment
| Age, Continuous(years) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Mean | 45.9 ± 10.52 | 48.5 ± 8.07 | 46.8 ± 8.19 | 47.4 ± 8.40 |
| Sex: Female, Male(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Female | 3 | 10 | 13 | 26 |
| Male | 8 | 29 | 28 | 65 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 39 | 41 | 91 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 11 | 37 | 39 | 87 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 1 | 3 |
| White | 0 | 0 | 1 | 1 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| HBsAg at screening(log10 IU/mL) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Mean | 2.774 ± 0.355 | 2.976 ± 0.348 | 2.902 ± 0.315 | 2.918 ± 0.337 |
| HBeAg at screening(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Negative | 9 | 30 | 31 | 70 |
| Positive | 2 | 9 | 10 | 21 |
| ALT at screening(U/L) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Mean | 26.8 ± 14.08 | 21.8 ± 7.48 | 20.3 ± 8.93 | 21.7 ± 9.23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Jul 2023, 26 months.
Results were first posted in Jul 2026, 3 years after primary completion. A results delay was requested in Jun 2024.
Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 26 months is above that.
Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elebsiran
Brii Biosciences Limited